×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Insmed Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 ARISE Study Of ...
PR Newswire
Patients Treated with ARIKAYCE Plus Macrolide-Based Background Regimen Had Meaningfully Greater Improvements in Respiratory Symptoms vs.
3 days ago
Insmed reports promising ARIKAYCE study results By Investing.com
Investing.com
BRIDGEWATER, N.J. - Insmed (NASDAQ:INSM) Incorporated (NASDAQ:INSM), a global biopharmaceutical company, today shared new data at the...
3 days ago
Have Insiders Sold Insmed Shares Recently?
Simply Wall Street
Some Insmed Incorporated ( NASDAQ:INSM ) shareholders may be a little concerned to see that the President, William...
1 day ago
Anticipation mounts as Insmed's bronchiectasis therapy nears phase 3 completion
biopharma-reporter.com
Over the past few years, Insmed has garnered attention for its pipeline candidate and bronchiectasis treatment, brensocatib.
1 week ago
Insmed Incorporated (NASDAQ:INSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Yahoo Finance
As you might know, Insmed Incorporated ( NASDAQ:INSM ) recently reported its quarterly numbers. The results weren't...
2 weeks ago
Insmed Unusual Options Activity For May 21 - Insmed (NASDAQ:INSM)
Benzinga
Whales with a lot of money to spend have taken a noticeably bearish stance on Insmed. Looking at options history for Insmed.
3 days ago
Insmed's brensocatib: A candidate for bronchiectasis treatment, closer to approval
Clinical Trials Arena
Insmed has been in the spotlight over the past few years for its pipeline agent, brensocatib, which has previously shown promising Phase II...
2 weeks ago
Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update
PR Newswire
ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $75.5 Million for the First Quarter of 2024, Reflecting 16% Annual...
2 weeks ago
Insider Sale: Chief Medical Officer Martina Flammer Sells Shares of Insmed Inc (INSM)
Yahoo Finance
On May 17, 2024, Martina Flammer, Chief Medical Officer of Insmed Inc (NASDAQ:INSM), sold 4642 shares of the company.
6 days ago
Insmed To Present at the BofA Securities Health Care Conference 2024
PR Newswire
PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with...
2 weeks ago